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Introduction {#sec001}
============

Renal cell carcinoma (RCC), the most common adult renal neoplasm, accounts for 2--3% of all cancers and 2% of all cancer-related deaths \[[@pone.0160570.ref001]--[@pone.0160570.ref003]\]. Clear cell RCC (cRCC) is the most common (70--85% of all renal cancers) and, probably, the most aggressive RCC subtype, characterized by the highest rate of local invasion, metastasis and mortality \[[@pone.0160570.ref002],[@pone.0160570.ref003]\]. Although substantial efforts have been made, so far, only few etiological factors, including obesity, hypertension, smoking and occupational exposure to certain toxic substances, have been identified as risk factors for RCC \[[@pone.0160570.ref002],[@pone.0160570.ref004]\].

The fact that recognized risk factors for RCC development are rather common in general population, but only a small group of exposed people will eventually develop RCC, suggests that the development of RCC can be partially explained by inter-individual genetic variations. Some observations suggest that cytosolic glutathione S-transferases (GST, EC 2.5.1.18) may be implicated not only in the development, but also in the progression of RCC \[[@pone.0160570.ref005]--[@pone.0160570.ref007]\]. GSTs represent a large enzyme family which members catalyze the conjugation of xenobiotics, including many anticancer drugs, with GSH \[[@pone.0160570.ref008],[@pone.0160570.ref009]\]. The main site for the initial glutathione conjugation of toxic compounds is generally assumed to be the liver, followed by a mandatory transfer of conjugates to the kidney \[[@pone.0160570.ref010]\]. Therefore, this pathway results mainly in detoxification and elimination of glutathione conjugates by the kidney \[[@pone.0160570.ref011]\]. However, not all reactions catalyzed by GSTs will result in detoxification. Namely, some GSTs are associated with bio-activation of occupational hazards, such as trichloroethylene, chlorophenols and pesticides \[[@pone.0160570.ref012]\], where the glutathione conjugate is more reactive than the parent compound. Moreover, it has been shown that the initial bio-activation step of some nephrocarcinogens can take place in the kidney itself \[[@pone.0160570.ref010],[@pone.0160570.ref011]\].

Furthermore, almost all members of eight classes of the mammalian cytosolic GSTs exhibit genetic polymorphism, resulting in complete lack or lowering of enzyme activity \[[@pone.0160570.ref009],[@pone.0160570.ref013]\]. As a result of polymorphic GST expression, great inter-individual differences in GST isoenzyme profiles exist in renal parenchyma \[[@pone.0160570.ref014]\], affecting both the biotransformation capacity of renal tissue and the potential genotoxicity of carcinogens. Since GSTs are involved in the biotransformation of several compounds recognized as risk factors for RCC \[[@pone.0160570.ref013]\], it is not surprising that cytosolic GST classes M1, T1 and P1 gained most attention in RCC as potential risk (GSTM1, GSTT1 and GSTP1) and chemoresistance determinants (GSTT1 and GSTP1) \[[@pone.0160570.ref006],[@pone.0160570.ref007],[@pone.0160570.ref011],[@pone.0160570.ref012]\]. Interestingly, alpha class of GSTs, which also posses peroxidase activity towards organic hydroperoxides and might be involved in regulation of cellular redox homeostasis in kidneys \[[@pone.0160570.ref015]\], has not been analyzed in such context in RCC as yet.

Furthermore, DNA adducts associated with tobacco smoking have been suggested as a marker of biologically effective dose of tobacco carcinogens that might improve individual cancer risk prediction \[[@pone.0160570.ref016]\]. Namely, cigarette smoke is a rich source of both free radicals, thought to be responsible for initiation of many tumors by inducing DNA damage that accumulates in cells, but also more than 60 carcinogens, among which sufficient evidence of carcinogenicity was found for polycyclic aromatic hydrocarbons (PAHs), such as benzo(a)pyrene \[[@pone.0160570.ref017]\]. Both free radicals and reactive PAH metabolites, such as \[+\]-anti-7,8-dihidroxy-9,10-oxy-7,8,9,10-tetrahydrobenzo(a)pyrene (\[+\]-anti-BPDE), a carcinogen produced from benzo(a)pyrene, are detoxified by GSTs \[[@pone.0160570.ref018],[@pone.0160570.ref019]\]. So far, the relationship between *GST* genotype and BPDE-DNA adduct formation in determining the risk for RCC has not been evaluated in patients with cRCC.

Due to the potential functional significance of common polymorphisms in genes encoding cytosolic glutathione transferase A1, M1, T1 and P1 in the onset of cRCC, it was of high importance to carry out a comprehensive study which would simultaneously determine the presence of established risk factors and specific gene variants in these patients, as well as, discern whether phenotype changes reflect genotype-associated risk.

Materials and Methods {#sec002}
=====================

Study population {#sec003}
----------------

Newly diagnosed cases of clear cell RCC, treated at the Urology Clinic, Clinical Center of Serbia, Belgrade, between the years of 2011--2013, were enrolled into this study. The cases comprised a total of 199 subjects (133 men, 66 women; average age 58.09±11.51 years) with histologically confirmed cRCC diagnosis, according to the 2004 WHO classification of Tumors \[[@pone.0160570.ref020]\] and 2009 TNM classification system \[[@pone.0160570.ref021]\]. Acceptance rate was 93% and the most common reason for no participation was personal. The control group initially comprised 454 healthy individuals (233 men, 221 women, average age 60.40±12.31years) who had undergone surgery for benign conditions at the same clinical center. The initial control group was further matched to cRCC patients according to gender and age, and finally included 274 individuals (184 men, 90 women; average age 59.77±10.96 years) with no previous personal history of cancer. The basic demographic data and assumed risk factors for RCC (including smoking history, obesity and hypertension) were obtained from the study subjects using the structured questionnaire \[[@pone.0160570.ref022]\] composed at the Institute of Epidemiology, Faculty of Medicine University in Belgrade, during the time of blood collection. In our study, obese patients were defined as individuals with BMI above 25 and smokers as individuals who reported every day smoking during a minimum of 60-day period prior to their enrollment in the study. Further on, participants were asked about the number of cigarettes smoked per day and duration of smoking. All collected data referred to a time period prior to the diagnosis of cRCC for the cases, and a corresponding period for the controls. The study was approved by the Institutional Ethical board (October 13^th^, 2011, approval number 29/X-3, Faculty of Medicine, University of Belgrade, Serbia) and was performed in accordance with principles of Helsinki declaration. Informed written consent was obtained from all recruited subjects.

DNA isolation and genotyping {#sec004}
----------------------------

Genomic DNA was isolated from whole peripheral blood and non-tumour tissue samples, using DNA kit (*Qiagen*, *USA*). DNA concentration was measured on GeneQuant*pro* (*Biochrom*, *England*).

The DNA sequences of *GSTM1* and *GSTT1* were analyzed by polymerase chain reaction (PCR) in Mastercycler gradient thermal cycler (*Eppendorf*, *Germany*) according to the method by Abdel-Rahman et al. \[[@pone.0160570.ref023]\]. The multiplex PCR technique used to detect homozygous deletions of *GSTM1* and *GSTT1* included primers for the *CYP1A1* housekeeping gene as an internal control for amplifiable DNA ([Table 1](#pone.0160570.t001){ref-type="table"}).

10.1371/journal.pone.0160570.t001

###### PCR: primer sequences, PCR conditions, restriction enzymes and fragment lengths.

![](pone.0160570.t001){#pone.0160570.t001g}

  Gene                       Primer sequences                                                   PCR protocol                                                                                                                                                          Gel electrophoresis results
  -------------------------- ------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  *GSTA1 C69T (rs3957357)*   F, 5′-GCATCAGCTTGCCCTTCA-3′; R, 5′-AAACGCTGTCACCGTCCTG-3′          Denature: 94°C for 4mins; Followed by 94°C for 20s; Annealing: 58°C for 20s; Extension: 72°C for 40s; \#cycles: 33; Final extension: 72°C for 5 mins;                 *Eam1104I* incubation at 37°C overnight; *GSTA1CC*- 400bp; *GSTA1CT*- 400bp, 308bp and 92bp; *GSTA1TT*- 308bp and 92bp;
  *GSTM1*                    F, 5′-GAACTCCCTGAAAAGCTAAAGC-3′; R, 5′-GTTGGGCTCAAATATACGGTGG-3′   Multiplex PCR: Denature: 94°C for 4mins; Followed by 94°C for 30s; Annealing: 59°C for 30s; Extension: 72°C for 45s; \#cycles: 30; Final extension: 72°C for 5mins;   *GSTM1-active*: 215bp band, *GSTM1-null*: no band
  *GSTT1*                    F, 5′-TTCCTTACTGGTCCTCACATCTC-3′; R, 5′-TCACCGGATCATGGCCAGCA-3′    *GSTT1*-*active*: 480bp band, *GSTT1*-*null*-: no band;                                                                                                               
  *CYP1A1*                   F, 5'-GAACTGCCACTT CAGCTGTCT-3'; R, 5'-CAGCTGCATTTG GAAGTGCTC-3'   312bp band;                                                                                                                                                           

The analysis of the SNP *GSTA1 C69T* (rs3957357) was performed using PCR-restriction fragment length polymorphism (RFLP) with *Eam1104I* (*Thermo Fisher Scientific*, *USA*) restriction enzyme according to the method by Ping et al \[[@pone.0160570.ref024]\] ([Table 1](#pone.0160570.t001){ref-type="table"}).

For analyses of SNP *GSTP1 Ile105Val* (rs1695), the real-time PCR (qPCR) allelic discrimination was performed on *Mastercyclerep realplex* (*Eppendorf*, *Germany*) using *Applied BiosystemsTaqMan*^*®*^ *Drug Metabolism Genotyping* assay according to the manufacturer's instructions (*Life Technologies*, *Applied Biosystems*, *USA*, *assay ID*: *C\_\_3237198_20*).

Researches that performed genotyping were unaware of the case-control status, and blinded quality control samples were inserted to validate genotyping identification procedures. Concordance for blinded samples was 100%.

Determination of BPDE-DNA adducts level {#sec005}
---------------------------------------

BPDE-DNA adducts levels (ng/ml) were measured in all DNA samples according to the standard method provided by *OxiSelect BPDE-DNA Adduct ELISA Kit* (*Cell Biolabs*, *Inc*., *USA*).

Statistical analysis {#sec006}
--------------------

In this study, the data of continuous variables were expressed as mean ± standard deviation (SD) or median (minimum-maximum) whereas categorical variables were presented using frequency (n, %) counts. Distribution was tested by using graphical methods, as well as *Kolmogorov---Smirnov* and *Shapiro-Wilk* tests. Differences in investigated parameters were assessed by using *Student's T* test for continuous data with normal distribution and *Mann---Whitney* rank-sum test for continuous data with non-normal distribution. Finally, χ2 test was used for categorical variables. The genetic variants and their risk for disease were computed by odds ratios (OR) and 95% confidence intervals (CI) by logistic regression analysis. With the smoking, obesity and hypertension being well established risk factors for RCC, OR was adjusted by these variables as potential confounders, as well as by age and gender. Calculations were performed using the *SPSS software* version 17.0 (*Chicago*, *IL*, *USA*). *P* value of ≤0.05 was considered to be statistically significant.

Results {#sec007}
=======

Baseline characteristics of patients with cRCC and respective controls are shown in [Table 2](#pone.0160570.t002){ref-type="table"}. As shown, cRCC patients and controls did not differ in terms of age, gender, obesity and smoking (p\>0.05). However, more than half of the cases (52%) suffered from hypertension compared to controls (26%).

10.1371/journal.pone.0160570.t002

###### Baseline characteristic of patients with cRCC and respective controls.
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  Variable                                                                                               cRCC patients       Controls           OR (95%CI)                                                p-value
  ------------------------------------------------------------------------------------------------------ ------------------- ------------------ --------------------------------------------------------- ---------
  **Age** (years)[^a^](#t002fn001){ref-type="table-fn"}                                                  58.09 ± 11.51       59.77±10.96        /                                                         0.11
  **Gender**, n (%)                                                                                                                                                                                       
  Male                                                                                                   133 (67)            184 (67)           1.00 (reference group)                                    
  Female                                                                                                 66 (33)             90 (33)            1.01 (0.68--1.49)                                         0.94
  **Hypertension**, n (%)[^i^](#t002fn008){ref-type="table-fn"}                                                                                                                                           
  No                                                                                                     75 (48)             191 (74)           1.00 (reference group)                                    
  Yes                                                                                                    82 (52)             67 (26)            3.07 (1.61--5.84)[^b^](#t002fn002){ref-type="table-fn"}   0.001
  **Obesity**, n (%)[^i^](#t002fn008){ref-type="table-fn"}                                                                                                                                                
  BMI below 25                                                                                           63 (40)             92 (38)            1.00 (reference group)                                    
  BMI above 25                                                                                           96 (60)             153 (62)           0.80 (0.43--1.46)[^c^](#t002fn003){ref-type="table-fn"}   0.47
  **BMI (**kg/m^2^**)**[^a^](#t002fn001){ref-type="table-fn"}^,^[^i^](#t002fn008){ref-type="table-fn"}   26.41±4.49          26.36±3.49         /                                                         0.89
  **Smoking**, n (%) [^i^](#t002fn008){ref-type="table-fn"}                                                                                                                                               
  Never                                                                                                  67 (41)             126 (48)           1.00 (reference group)                                    
  Ever[^d^](#t002fn004){ref-type="table-fn"}                                                             97 (59)             138 (52)           1.44 (0.90--2.29)[^e^](#t002fn005){ref-type="table-fn"}   0.12
  **Pack-years**[^f^](#t002fn006){ref-type="table-fn"}                                                   30 (1.35--141.00)   30 (0.10--88.00)   /                                                         0.24
  **Fuhrman grade**, n (%)[^g^](#t002fn007){ref-type="table-fn"}                                                                                                                                          
  Grade I                                                                                                21 (13)             /                  /                                                         
  Grade II                                                                                               89 (55)             /                  /                                                         
  Grade III                                                                                              48 (29)             /                  /                                                         
  Grade IV                                                                                               5 (3)               /                  /                                                         
  **pT stage**, n (%)[^h^](#t002fn007){ref-type="table-fn"}                                                                                                                                               
  pT1                                                                                                    78 (42)             /                  /                                                         
  pT2                                                                                                    23 (13)             /                  /                                                         
  pT3                                                                                                    78 (42)             /                  /                                                         
  pT4                                                                                                    5 (3)               /                  /                                                         

^a^Mean ±SD;

^b^OR, odds ratio adjusted to age, gender, pack-years, BMI (body mass index);

^c^OR, odds ratio adjusted to age, gender, pack-years, hypertension;

^d^ Every day smoking during a minimum of 60-day period prior to the study onset;

^e^OR, odds ratio adjusted to age, gender, BMI, hypertension; CI, confidence interval;

^f^Median (min-max);

^g,\ h^Available data on patients' tumor grade and stage, depending on the type of surgery and pathohistology diagnostics;

^i^Based on the available data.

GST genotypes and cRCC risk {#sec008}
---------------------------

The frequency of *GSTM1-null* genotype was higher (56%) in cRCC patients than in controls (50%) and individuals with *GSTM1-null* genotype were at 2.07-fold higher risk of cRCC development (95%CI:1.11--3.84, p = 0.02) ([Table 3](#pone.0160570.t003){ref-type="table"}). On the other hand, no significant association with cRCC risk was found for *GSTT1-active* genotype (OR = 1.08, 95%CI:0.52--2.27, p = 0.82). Regarding SNP polymorphisms, the obtained results showed the lack of the *GSTA1 C69T* polymorphism effect on cRCC risk, since the carriers of *GSTA1 CT+TT (low-activity)* genotype were not at increased risk of cRCC in comparison with individuals with *GSTA1*-*active* genotype (OR = 1.19, 95%CI:0.63--2.25, p = 0.58). Interestingly, carriers of *GSTP1 IleVal+ValVal* (*variant)* genotype (77% of cRCC patients compared to 58% of controls) were at 3.14-fold increased risk of cRCC (95%CI:1.54--6.43, p\<0.001) ([Table 3](#pone.0160570.t003){ref-type="table"}).

10.1371/journal.pone.0160570.t003

###### *GST* genotypes in relation to the risk of cRCC.
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  *GST* genotype                                                    cRCC patients n, %   Controls n, %   OR (95%CI)[^e^](#t003fn005){ref-type="table-fn"}   p- value
  ----------------------------------------------------------------- -------------------- --------------- -------------------------------------------------- ----------
  ***GSTM1***                                                                                                                                               
  *Active*[^a^](#t003fn001){ref-type="table-fn"}                    87 (44)              137 (50)        1.00 (reference group)                             
  *Null*[^b^](#t003fn002){ref-type="table-fn"}                      109 (56)             137 (50)        2.07 (1.11--3.84)                                  0.02
  ***GSTT1***                                                                                                                                               
  *Null*[^b^](#t003fn002){ref-type="table-fn"}                      44 (22)              71 (26)         1.00 (reference group)                             
  *Active*[^a^](#t003fn001){ref-type="table-fn"}                    152 (78)             203 (74)        1.08 (0.52--2.27)                                  0.82
  ***GSTA1*** (rs 3957357)                                                                                                                                  
  *CC*                                                              65 (33)              112 (41)        1.00 (reference group)                             
  *CT+TT (low activity)*[^c^](#t003fn003){ref-type="table-fn"}      132 (67)             162 (59)        1.19 (0.63--2.25)                                  0.58
  ***GSTP1*** (rs1695)                                                                                                                                      
  *IleIle (wild-type)*                                              44 (23)              115 (42)        1.00 (reference group)                             
  *IleVal+ValVal (variant)*[^d^](#t003fn004){ref-type="table-fn"}   150 (77)             159 (58)        3.14 (1.54--6.43)                                  \<0.001

^a^Active, if at least one active allele present;

^b^Null if no active alleles present;

^c^Low activity, if at least one *T* allele present.

^d^Variant, if at least one *Val* allele present;

^e^OR, odds ratio adjusted to age, gender, pack-years, BMI, hypertension; CI, confidence interval; Deletion *GSTM1* and *GSTT1* genotypes were investigated in 196 cases and all recruited controls. SNP polymorphism *GSTA1 C69T* and *GSTP1 Ile105Val* were analyzed in 197 and 194 cRCC cases, respectively, and all recruited controls.

### Combined effect of GST genotypes on risk of cRCC {#sec009}

Combined effect on cRCC risk was tested for all genotypes ([Table 4](#pone.0160570.t004){ref-type="table"}). No significant association, in terms of cRCC risk, was established when the combined effect of any two of *GSTM1*, *GSTA1* and *GSTT1* genotypes were assessed (p\>0.05). On the other hand, a statistically significant association between *GST* polymorphism and susceptibility to cRCC was found when the effect of *GSTP1-variant* genotype was analyzed in combination with the other three genotypes (*GSTP1-variant* and *GSTM1-null* OR = 11.23, 95%CI:2.62--48.08, p\<0.001; *GSTP1-variant* and *GSTA1low-activity* OR = 4.93, 95%CI:1.48--16.43, p = 0.009; *GSTP1-variant* and *GSTT1-active* OR = 4.10, 95%CI:0.95--17.35, p = 0.05).

10.1371/journal.pone.0160570.t004

###### Combined effect of *GST* genotypes on risk of cRCC.
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  *GST* genotype                                         *GSTM1*                                      *GSTA1*               *GSTP1*                                                                                                        
  ------------------------------------------------------ -------------------------------------------- --------------------- -------------------------------------------- -------------------- -------------------------------------------- --------------------
  ***GSTA1*** (rs3957357)                                                                                                                                                                                                                  
  *Active*[^a^](#t004fn001){ref-type="table-fn"}                                                                                                                                                                                           
  Ca (%)/Co(%)                                           29(15)/54(20)                                35(18)/58(21)         \-                                           \-                   \-                                           \-
  OR (95%CI)[^e^](#t004fn005){ref-type="table-fn"}       1.00[^f^](#t004fn006){ref-type="table-fn"}   2.14 (0.67--6.86)     \-                                                                \-                                           
  *p-value*                                              \-                                           0.19                  \-                                           \-                   \-                                           \-
  *Low-activity*[^c^](#t004fn003){ref-type="table-fn"}                                                                                                                                                                                     
  Ca/Co                                                  58(30)/83(30)                                73(37)/79(29)         \-                                           \-                   \-                                           
  OR (95%CI)[^e^](#t004fn005){ref-type="table-fn"}       1.03 (0.41--2.61)                            2.00 (0.79--5.07)     \-                                           \-                   \-                                           \-
  *p-value*                                              0.94                                         0.14                  \-                                           \-                   \-                                           \-
  ***GSTP1*** (rs1695)                                                                                                                                                                                                                     
  *Wild-type*                                                                                                                                                                                                                              
  Ca (%)/Co(%)                                           17(9)/55(20)                                 27(14)/60(22)         17(9)/54(20)                                 26(13)/61(22)        \-                                           
  OR (95%CI)[^e^](#t004fn005){ref-type="table-fn"}       1.00[^f^](#t004fn006){ref-type="table-fn"}   5.63 (1.11--28.53)    1.00[^f^](#t004fn006){ref-type="table-fn"}   3.40 (0.72--16.00)   \-                                           \-
  *p-value*                                              \-                                           0.03                  \-                                           0.12                 \-                                           \-
  *Variant*[^d^](#t004fn004){ref-type="table-fn"}                                                                                                                                                                                          
  Ca (%)/Co(%)                                           67(35)/82(30)                                81(42)/77(28)         46(24)/58(21)                                103 (54)/101(36)     \-                                           \-
  OR (95%CI)[^e^](#t004fn005){ref-type="table-fn"}       4.40 (1.17--16.46)                           11.23 (2.62--48.08)   5.39 (1.42--20.39)                           4.93 (1.48--16.43)   \-                                           \-
  *p-value*                                              0.02                                         \<0.001               0.01                                         0.009                \-                                           \-
  ***GSTT1***                                                                                                                                                                                                                              
  *Active*[^a^](#t004fn001){ref-type="table-fn"}                                                                                                                                                                                           
  Ca (%)/Co(%)                                           67(34)/102(37)                               85(44)/101(36)        53(27)/82(30)                                99 (51)/121(44)      37(19)/85(31)                                113(59)/118(43)
  OR (95%CI)[^e^](#t004fn005){ref-type="table-fn"}       1.57 (0.49--5.01)                            2.78 (0.80--9.64)     3.32 (0.72--15.22)                           2.62(0.65--10.58)    2.47 (0.37--10.37)                           4.10 (0.95--17.35)
  *p-value*                                              0.43                                         0.10                  0.12                                         0.17                 0.34                                         0.05
  *Null*[^b^](#t004fn002){ref-type="table-fn"}                                                                                                                                                                                             
  Ca (%)/Co(%)                                           20(10)/35(13)                                24(12)/36(14)         11(6)/30(11)                                 32 (16)/41(15)       7(4)/30(11)                                  35(18)/41(15)
  OR (95%CI)[^e^](#t004fn005){ref-type="table-fn"}       1.00[^f^](#t004fn006){ref-type="table-fn"}   3.36 (0.77--14.66)    1.00[^f^](#t004fn006){ref-type="table-fn"}   3.57 (0.72--17.72)   1.00[^f^](#t004fn006){ref-type="table-fn"}   4.47 (0.72--27.43)
  *p-value*                                              \-                                           0.10                  \-                                           0.11                 \-                                           0.10

^a^Active, if at least one active allele present.

^b^Null, if no active alleles present.

^c^Low activity, if at least one *T* allele present.

^d^Variant, if at least one *Val* allele present;

^e^OR, odds ratio adjusted to age, gender, pack-years, BMI, hypertension; CI, confidence interval; Ca, number of cRCC patients; Co, controls;

^f^Reference group.

Finally, when the combined effect of all four *GST* genotypes was analyzed, we found striking evidence in favor of increased susceptibility to cRCC in patients with, what it seems to be, "risk carrying genotype combination": *GSTM1-null*, *GSTT1-active*, *GSTA1 low-activity* and *GSTP1-variant*. It is important to note that such individuals comprised 22% of all recruited cRCC patients, in comparison with 12% of control subjects, and exhibited 9.32-fold elevated risk compared to carriers of combined *GSTM1-active*, *GSTT1-null*, *GSTA1-active and GSTP1 wild-type* genotypes (95%CI:1.08--80.18, p = 0.04, [Table 5](#pone.0160570.t005){ref-type="table"}).

10.1371/journal.pone.0160570.t005

###### *GST* genotypes in relation to the risk of cRCC.

![](pone.0160570.t005){#pone.0160570.t005g}

  *GST* genotype combination                                                                                                                                                                                                  cRCC patients n, %   Controls n, %   OR (95%CI)[^e^](#t005fn005){ref-type="table-fn"}   p---value
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- --------------- -------------------------------------------------- -----------
  *GSTM1-active*[^a^](#t005fn001){ref-type="table-fn"}*/GSTT1-null*[^b^](#t005fn002){ref-type="table-fn"}*/GSTA1 active* /*GSTP1-wild type*                                                                                   1 (1)                7 (3)           1.00 (reference group)                             
  *GSTM1-null*[^b^](#t005fn002){ref-type="table-fn"} */GSTT1-active*[^a^](#t005fn001){ref-type="table-fn"}*/GSTA1 low-activity*[^c^](#t005fn003){ref-type="table-fn"}/*GSTP1-variant*[^d^](#t005fn004){ref-type="table-fn"}   43 (22)              34 (12)         9.32 (1.08--80.18)                                 0.04

^a^Active, if at least one active allele present;

^b^Null if no active alleles present;

^c^Low activity, if at least one *T* allele present.

^d^Variant, if at least one *Val* allele present;

^e^OR, odds ratio adjusted to age and gender; CI, confidence interval. Genotype combinations were investigated in 194 cases and all recruited controls; *GSTM1-active*^*a*^*/GSTT1-null*^*b*^*/GSTA1 active*/*GSTP1-wild type-* "Reference genotype combination"; *GSTM1-null*^*b*^*/GSTT1-active*^*a*^*/GSTA1low-activity*^*c*^/*GSTP1-variant*^*d*^- "Risk carrying genotype combination".

Combined effect of GST polymorphism and recognized risk factors for cRCC {#sec010}
------------------------------------------------------------------------

Results on the combined effect of *GST* polymorphism and exposure to recognized risk factors for cRCC development are shown in [S1 Table](#pone.0160570.s001){ref-type="supplementary-material"}. As presented, significant modifying effect on risk of cRCC conferred by hypertension had individuals with either *GSTM1-null*, *GSTT1-active*, *GSTA1 low-activity* or *GSTP1-variant* genotype. Namely, they were at increased risk of cRCC when compared to the normotensive *GSTM1-active*, *GSTT1-null*, *GSTA1-active* or *GSTP1 wild-type* individuals (OR = 6.01, 95%CI:2.48--14.52, p\<0.001; OR = 3.27, 95%CI:1.20--8.91, p = 0.02; OR = 3.85, 95%CI:1.54--9.58, p = 0.004 and OR = 8.29, 95%CI:3.12--22.04, p\<0.001 respectively, [S1A Table](#pone.0160570.s001){ref-type="supplementary-material"}). Another factor that contributed significantly to risk of cRCC, only in carriers of *GSTP1-variant* genotype, was smoking (OR = 3.70, 95%CI:1.75--7.83, p = 0.001, [S1C Table](#pone.0160570.s001){ref-type="supplementary-material"}).

GST genotypes and cRCC risk in smokers {#sec011}
--------------------------------------

Further on, we focused on the population of smokers ([Table 6](#pone.0160570.t006){ref-type="table"}). Significant association between *GST* genotype and the risk of cRCC in smokers was found only for the *GSTP1* genotype. Namely, smokers with *GSTP1-variant* genotype were at 2.87-fold higher risk of developing cRCC (OR = 2.87, 95%CI:1.45--5.69, p = 0.002) than smokers carrying *GSTP1 wild-type* genotype. Although *GSTM1-null* genotype did not, at least independently, significantly affect the risk of cRCC in smokers (OR = 1.71, 95%CI:0.95--3.06, p = 0.07), when present in combination with *GSTP1-variant* genotype, it contributed in a way that smokers with *GSTM1-null/GSTP1-variant* genotype exhibited 5.4--fold increased risk of cRCC (95%CI:1.74--16.98, p = 0.004) in comparison with carriers of *GSTM1-active/GSTP1 wild-type* genotype. In this manner, we confirmed the results obtained on the whole study population. The observed effect of combined *GSTM1-null/GSTP1-variant* genotype on cRCC risk was even more pronounced when *GSTA1 low-activity* genotype was included. Namely, *GSTM1-null/GSTP1-variant/GSTA1 low-activity* combination of genotypes, which was present in 94% of smokers with cRCC, as opposed to 70% in controls, increased the risk of cRCC up to 7.57 (95%CI:1.26--45.30,p = 0.02).

10.1371/journal.pone.0160570.t006

###### The association between *GST* genotypes and the levels of BPDE-DNA adducts in cRCC smokers.

![](pone.0160570.t006){#pone.0160570.t006g}

  *GST* genotypes in smokers                                                            cRCC smokers n,%   Controls- smokers n,%   OR (95%CI)[^e^](#t006fn005){ref-type="table-fn"}   p-value   BPDE-DNA adducts in cRCC smokers (ng/ml)[^g^](#t006fn007){ref-type="table-fn"}   p-value
  ------------------------------------------------------------------------------------- ------------------ ----------------------- -------------------------------------------------- --------- -------------------------------------------------------------------------------- ---------
  ***GSTM1***                                                                                                                                                                                                                                                                    
  *Active*[^a^](#t006fn001){ref-type="table-fn"}                                        37 (39)            80 (58)                 1.00[^f^](#t006fn006){ref-type="table-fn"}                   2.13 (1.39--5.22)                                                                
  *Null*[^b^](#t006fn002){ref-type="table-fn"}                                          57 (61)            58 (42)                 1.71 (0.95--3.06)                                  0.07      2.74 (1.64--17.93)                                                               
  ***GSTT1***                                                                                                                                                                                                                                                                    
  *Null*[^a^](#t006fn001){ref-type="table-fn"}                                          23 (24)            30 (22)                 1.00[^f^](#t006fn006){ref-type="table-fn"}                   2.81 (1.51--8.55)                                                                
  *Active*[^b^](#t006fn002){ref-type="table-fn"}                                        71 (76)            108 (78)                1.07 (0.53--2.15)                                  0.84      2.37 (1.39--17.93)                                                               0.32
  ***GSTA1*** (rs3957357)                                                                                                                                                                                                                                                        
  *Active*                                                                              23 (25)            46 (33)                 1.00[^f^](#t006fn006){ref-type="table-fn"}                   2.50 (1.39--8.55)                                                                
  *Low-activity*[^c^](#t006fn003){ref-type="table-fn"}                                  67 (75)            92 (67)                 1.21 (0.65--2.25)                                  0.53      2.50 (1.39--17.93)                                                               0.61
  ***GSTP1*** (rs1695)                                                                                                                                                                                                                                                           
  *Wild-type*                                                                           16 (17)            53 (38)                 1.00[^f^](#t006fn006){ref-type="table-fn"}                   2.50 (1.76--6.95)                                                                
  *Variant*[^d^](#t006fn004){ref-type="table-fn"}                                       77 (83)            85 (62)                 2.87 (1.45--5.69)                                  0.002     2.44 (1.39--17.39)                                                               0.65
  ***GSTM1****/* ***GSTP1***                                                                                                                                                                                                                                                     
  *GSTM1-active/ GSTP1 wild-type*                                                       5 (10)             27 (46)                 1.00[^f^](#t006fn006){ref-type="table-fn"}                   2.00 (1.76--2.75)                                                                
  *GSTM1-null/GSTP1-variant*[^d^](#t006fn004){ref-type="table-fn"}                      45 (90)            32 (54)                 5.44 (1.74--16.98)                                 0.004     2.50 (1.64--17.93)                                                               0.34
  ***GSTM1/GSTA1/GSTP1***                                                                                                                                                                                                                                                        
  *GSTM1-active/GSTA1-active/GSTP1 wild-type*                                           2 (6)              10 (30)                 1.00[^f^](#t006fn006){ref-type="table-fn"}                   2.37 (2.01--2.75)                                                                
  *GSTM1 null/GSTA1-low activity/GSTP1-variant*[^d^](#t006fn004){ref-type="table-fn"}   32 (94)            23 (70)                 7.57 (1.26--45.30)                                 0.02      2.44 (1.64--17.93)                                                               0.81

^a^Active, if at least one active allele present;

^b^Null, if no active alleles present;

^c^Low activity, if at least one *T* allele present;

^d^Variant, if at least one *Val* allele present;

^e^OR odds ratio adjusted to age, gender, BMI, hypertension; CI, confidence interval;

^f^Reference group;

^g^Median (min-max);

Deletion *GSTM1* and *GSTT1* genotypes were investigated in 94 out of 97 cRCC-smokers and all recruited controls-smokers (138). SNP polymorphism *GSTA1 C69T* and *GSTP1 Ile105Val* were analyzed in 90 out of 97 and 93 out of 97 cRCC-smokers, respectively, and all recruited controls-smokers (138).

The levels of BPDE-DNA adducts were initially compared between non-smokers (2.19 ng/ml (1.39--8.67)) and smokers (2.50 ng/ml (1.39--17.93)) with cRCC, however, no statistical significance was reached (p = 0.40). In an attempt to discern whether phenotype changes reflect genotype-associated risk of cRCC, comparative analysis of BPDE-DNA adduct levels in cRCC smokers who were carriers of *active/wild-type* versus *null/low-activity/variant* genotype, individually or in combination, was performed. These results have shown that smokers with *GSTM1-null* genotype had significantly higher concentration of BPDE-DNA adducts (2.74 ng/ml (1.64--17.93)) in comparison with *GSTM1-active* smokers (2.13ng/ml (1,39--5.22), p = 0.05) ([Table 6](#pone.0160570.t006){ref-type="table"}).

Discussion {#sec012}
==========

It has been suggested that differential GST expression in the kidney could affect the risk of RCC development. Among four common *GST* polymorphisms analyzed in this study, the *GSTM1-null* and *GSTP1-variant* genotypes showed a significant individual association with cRCC risk, which was even more pronounced in their combination. Furthermore, 22% of all recruited cRCC patients were carriers of combined *GSTM1-null*, *GSTT1-active*, *GSTA1 low-activity* and *GSTP1-variant* genotype, which might be considered as "risk-carrying genotype combination", since these individuals had 9.32-fold increased susceptibility to cRCC.

Due to a complex process of RCC development and progression, so far, it has not been feasible to identify a single biomarker for clinical application. Hence, panel of candidate genes, with respect to their different cellular functions, are currently being investigated as the part of potential future marker profile for RCC, including GSTs \[[@pone.0160570.ref002]\]. However, available data on *GST* polymorphism and RCC are rather inconsistent.

The deletion of *GSTM1* gene is one of the most investigated *GST* polymorphisms, since it has been suggested that a common variation within the *GSTM1* gene can modify the predisposition to various cancers, including RCC \[[@pone.0160570.ref013],[@pone.0160570.ref025]\]. The results of this study showed an impact of *GSTM1-null* genotype on cRCC risk, since carriers of this genotype were in 2.07-fold increased risk of developing clear cell RCC. Interestingly, although this result confirmed our preliminary findings on the association between *GSTM1* deletion polymorphism and susceptibility to RCC \[[@pone.0160570.ref026]\], it seems to be in contrast to majority of available data \[[@pone.0160570.ref005],[@pone.0160570.ref006],[@pone.0160570.ref011],[@pone.0160570.ref012],[@pone.0160570.ref027]--[@pone.0160570.ref029]\]. However, this refers only to *GSTM1-null* genotype as individual risk factor for RCC, while it has been suggested that when present together with polymorphisms in certain genes related to activation or detoxification of renal carcinogens (*CYP1A1*, *GSTT1*, *GSTP1*, *NAT2*), *GSTM1-null* genotype is associated with risk of RCC \[[@pone.0160570.ref030]\]. A possible explanation for discrepancy in obtained results might be that some studies were conducted on different subtypes of RCC and not on cRCC only. Besides, patients with inter-ethnic differences might have been included althoughit has been shown that ethnicity strongly affects genetic variability of GSTs \[[@pone.0160570.ref031]\]. Still, further elucidation of the role of *GSTM1* polymorphism in cRCC development is based on our results which have shown, for the first time in cRCC smokers, the association between the levels of BPDE-DNA adducts and *GSTM1-null* genotype.

Another widely investigated GST polymorphism, *GSTT1*, seems to be even more controversial \[[@pone.0160570.ref005],[@pone.0160570.ref006],[@pone.0160570.ref029]\]. Namely, it seems that *GSTT1-active* genotype is a risk factor for cRCC, since sometimes GSTT1-dependent conjugation of xenobiotics produces even more toxic compounds \[[@pone.0160570.ref013],[@pone.0160570.ref032]\]. Such a mechanism would explain the greater sensitivity of *GSTT1-active* individuals to RCC, especially after high and long-term exposure to occupational hazards \[[@pone.0160570.ref032]\]. However, our results on the lack of association between the *GSTT1* polymorphism and susceptibility to clear cell RCC are in agreement with the most recent meta-analysis of Yang et al. \[[@pone.0160570.ref006]\], although few studies have reported the association between *GSTT1-active* genotype independently \[[@pone.0160570.ref027]\] or in association with exposure to environmental or occupational hazards \[[@pone.0160570.ref011],[@pone.0160570.ref033],[@pone.0160570.ref034]\] and risk of RCC. Similar to *GSTM1* polymorphism, the same variation factors might be responsible for the conflicting results.

Although it has been shown that expression of alpha class of GSTs might be used as a highly specific diagnostic marker of clear cell RCC \[[@pone.0160570.ref001]\], polymorphic expression of GSTA1 has not been evaluated, as yet, in these patients. This is even more surprising, considering the fact that GST alpha is predominantly expressed in the proximal convoluted tubule, the main site of nephrotoxins and renal carcinogens toxicity \[[@pone.0160570.ref035]\], and from which clear cell RCC originates \[[@pone.0160570.ref036],[@pone.0160570.ref037]\]. However, our results have shown that *GSTA1* polymorphism does not, at least independently, affect susceptibility to cRCC.

The inconsistence in the results regarding the role of *GSTP1* polymorphism in risk of RCC is present, just like in other *GST* polymorphisms. Therefore, some of the available data suggest that GSTP1 may play a key role in the metabolism of environmental carcinogens, hence affecting the risk of RCC \[[@pone.0160570.ref027]\]. This is in agreement with the results obtained in our study. Namely, we have shown that carriers of *GSTP1-variant* genotype were in 3.14-fold increased risk of developing cRCC in comparison with carriers of *GSTP1 wild-type* genotype. On the contrary, some studies have shown that polymorphic expression of GSTP1 is not associated to susceptibility to RCC \[[@pone.0160570.ref006],[@pone.0160570.ref007],[@pone.0160570.ref012]\]. Once again, genetic background or environmental differences may contribute to the discrepancy in the results. However, since it is already established that, compared to normal kidney, RCC contains significantly lower GSTP1 activity \[[@pone.0160570.ref027]\], it is possible that GSTP1 might act as local modifier of renal cancer tumorigenesis. Despite the fact that BPDE detoxification is partially mediated by GSTP1, with the different variants showing different substrate specificity \[[@pone.0160570.ref009]\], we failed to find any significant correlation between *GSTP1* polymorphism and BPDE-DNA adducts, suggesting that some other GSTP1 substrates might also be important in cRCC development. On the other hand, it has been shown that GSTP1 may have other functions besides detoxification \[[@pone.0160570.ref038]\]. Namely, GSTP1 was shown to be an endogenous inhibitor of c-Jun N-terminal kinase 1 (JNK1), a kinase involved in stress response, apoptosis and cellular proliferation \[[@pone.0160570.ref038]\]. Furthermore, Thevenin et al. \[[@pone.0160570.ref039]\] have shown that *GSTP1* variant *Val* allele is a better JNK1 inhibitor, hence with the greater anti-apoptotic effect than the *wild-type Ile* allele \[[@pone.0160570.ref039]\].

Apart from investigating the association of specific *GST* polymorphisms with cRCC independently, the next step in our analysis was to evaluate the presence of any joint or linear cumulative effect of *GST* gene variants with respect to cRCC risk. Interestingly, we found that 22% of all recruited cRCC patients in our study were carriers of combined *GSTM1-null*, *GSTT1-active*, *GSTA1 low-activity* and *GSTP1-variant* genotype, suggesting that this combination of *GST* genotypes might be considered as „risk-carrying genotype combination" in clear cell RCC. So far, Ahmad et al. \[[@pone.0160570.ref040]\] have found that three-way combination of *GSTM1-null*, *GSTT1-null* and *GSTP1-variant* genotypes resulted in 4.5-fold increase in RCC risk, which is partially in agreement with our results, while Sweeny et al. \[[@pone.0160570.ref012]\] have shown an elevated risk of RCC in carriers of *GSTT1-null* genotype in all combinations of *GSTM1* and *GSTP1* genotypes. Our results on the increased risk of cRCC in carriers of *GSTM1-null/GSTA1-low activity/GSTP1-variant* genotype, obtained in the population of smokers, further support the results obtained on the whole study population. Unfortunately, none of the cRCC patients that were smokers had the four-way „risk-carrying genotype combination".

Regarding combined effect of *GST* polymorphisms and hypertension on clear cell RCC risk, it seems that hypertension contributes to genotype-associated cRCC risk in all examined polymorphisms, once again with special emphasis on *GSTM1-null* and *GSTP1-variant* genotypes. This is probably due to significant antioxidant role of GSTs, since oxidative stress is recognized as an important pathogenetic factor in the development of hypertension \[[@pone.0160570.ref031]\]. In this line, it has been suggested that determination of *GST* genotypes may help in identifying individuals at high-risk for hypertension \[[@pone.0160570.ref041]\]. Recently, Manevich et al. \[[@pone.0160570.ref042]\] have shown that *GSTP1* genetic variants differentially mediate activation of peroxiredoxin VI (PRDX6), the dual-functioning antioxidant enzyme which detoxifies lipid peroxides. Furthermore, *GSTP1-variant* genotype seems to be less effective in forming a heterodimer with PRDX6, implying that *GSTP1-variant* individuals will have significantly lower capacity for mounting an antioxidant response, particularly affecting protection of cell membranes against lipid peroxidation \[[@pone.0160570.ref042]\].

This study has several limitations that need to be addressed. The case-control design was used for estimating of associations between *GST* genotypes and risk of cRCC and therefore the selection bias might influence the results. Additionally, recall bias regarding the recognized risk factors for RCC development might have influenced the results as well. Furthermore, the data on environmental or occupational exposure were not validated, hence not used in the analysis of the obtained results. Our control group was hospital-based and relatively small. Therefore, the use of population controls may have been more appropriate. In this line, the study subjects were white only, therefore the possible effect of ethnicity could not be evaluated. Moreover, the BPDE-DNA adduct levels were not determined in control population.

In summary, despite the above-mentioned limitations, the present study supports the hypothesis that *GSTM1*, *GSTT1*, *GSTA1* and *GSTP1* polymorphisms might be associated to the risk of cRCC, with special emphasis on *GSTM1-null* and *GSTP1-variant* genotypes. Furthermore, combined *GSTM1-null*, *GSTT1-active*, *GSTA1 low activity* and *GSTP1-variant* genotypes might be considered as "risk-carrying genotype combination" in clear cell RCC. More case-control studies which would analyze the association between *GST* gene variants, independently or in combination, and RCC risk, conducted on larger sample sizes, which would include patients from different geographic areas, exposed to various environmental factors and occupational hazards, known to be associated to RCC development. Only in that way accurate analysis of interactions between RCC contributing factors would be possible, including gene-environmental and gene-gene interactions.
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